About us
Culture
News & Events
CREATE

Since its establishment in 2001, Create Group has remained committed to advancing human healthcare through pioneering medical innovations. Our products and investments span multiple medical domains including breath diagnostics solutions, AI-powered diagnostic platforms, non-invasive early screening technologies for diabetes and innovative multi-omics precision diagnostic solutions for diabetes and coronary heart disease, alongside targeted therapeutic development projects.

As an innovation-driven enterprise with over two decades of dedication to the health industry, we have established a comprehensive industry chain ecosystem integrating investment, R&D, production, sales and integrated services. Faithfully pursuing our corporate mission of "Safeguarding Human Health through Technological Innovation", we upholds "Innovation Knows No Bounds" as our cultural ethos. Guided by scientific advancement, we continuously invest in R&D resources, pursue exceptional quality, and aspire to become a guardian of human health.

Products

I 【Breath Test Analyzer】

A single breath for multiple diagnoses

     
  • H₂: Small Intestinal Bacterial Overgrowth (SIBO) | Gastrointestinal Motility Disorders | Carbohydrate Malabsorption | Oro-Cecal Transit Time | Pancreatic Exocrine Insufficiency
  • CH₄: Intestinal Methanogen Overgrowth (IMO)
  • CO: Red Blood Cell Lifespan
  • VSC: Halitosis and Its Underlying Etiology (Upcoming Feature)

II 【Deepseek Intelligent Agent + Standardized Medical Conclusion Coding (ICD-10) Intelligent Assistance System】

Overcoming industry challenges with innovative solutions

  • Medical knowledge repository built on ICD-10 international standards
  • AI-powered personalized guidance recommendations leveraging historical data
  • Self-adaptive AI learning to optimize system performance in health examination center
  • AI-enabled quality control for primary diagnostic data, generating high-precision medical reports
  • Automatically identifies Class A and B critical positive results per national guidelines, enabling timely follow-up and management
  • 80% reduction in primary diagnosis time, optimized talent allocation, and lowered operational costs

III 【Non-invasive Screening for Early-Stage Diabetes Mellitus】

Early Warning/Non-Invasive/Rapid Test

     
  • Advanced Glycation End Products (AGEs) Detection
    •  
  • Diabetic Retinopathy Evaluation
    •  
  • Diabetic Neuropathy Evaluation
    •  
  • Diabetic Nephropathy Evaluation
    •  
  • Diabetic Cardiovascular and Cerebrovascular Complications Evaluation
    •  

IV 【Innovative Multi-Omics Precision Prediction, Diagnosis, and Targeted Therapeutic Development Program for Diabetes and Coronary Heart Disease】

Leveraging multi-omics technologies to achieve precise prediction and diagnosis

     
  • Precision Medication Guidance for Current Patients
  • Precision Prevention Strategies for High-Risk Populations
  • Drug Target Development for Diabetes and Coronary Heart Disease
  • Focusing on Arteriosclerotic Cardiovascular Disease (ASCVD) and Diabetes-Related Genes
  • Enhancing precision diagnosis through protein-based detection and genetic analysis